

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/943,446	08/30/2001	Tessa A. Castleberry	PC10891AGPR

CONFIRMATION NO. 9426

FORMALITIES LETTER



OC000000007806275

Gregg C. Benson
Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, CT 06340

Date Mailed: 04/05/2002

NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Filing Date Granted

The U.S. Patent and Trademark Office has received your reply on 03/15/2002 to the Notice to File Missing Parts (Notice) mailed 10/15/2001 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file


202240 042460

in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

202209041650



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 15th day of April, 2002.

By

(Signature of person mailing)
Jennifer A. Kispert

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: TESSA A. :
CASTLEBERRY, ET AL.

APPLICATION NO.: 09/943,446 : **Examiner:** To be assigned
FILING DATE: AUGUST 30, 2001 : **Group Art Unit:** To be assigned
TITLE: CANINE PARATHYROID HORMONE 1 :
RECEPTOR

Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

REPLY TO NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

This is in reply to the Office Action mailed October 15, 2001 in the above-identified Application and having an original period for response of three months. A PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a) was filed on March 15, 2002 that respectfully requested that the term for response to the Examiner's Action in this application, mailed on October 15, 2001, and having an original period for response of two months, which expired on December 15, 2001, be extended by three months, such that it included and expired on March 15, 2002. A PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a) is being filed on even date herewith that respectfully requests that the term for response to the Examiner's Action in this application, mailed on October 15, 2001, and having an original period for response of two months, which expired on December 15, 2001, previously extended by three months such that it included and expired on March 15, 2002, be further extended by an additional month, such that it includes and expires on April 15, 2002.

2022-04-20 09:44:00

The NOTICE TO FILE MISSING PARTS, mailed on October 15, 2001, and having an original period for response of two months which is now being extended to include and expire on April 15, 2002, identified the following items as missing:

- (a) the oath or declaration;
- (b) substitute drawings in compliance with 37 CFR §1.84; and
- (c) an initial computer readable form (CRF) copy of the "Sequence Listing," an initial paper or compact disc copy of the "Sequence Listing," as well as an amendment directing its entry into the application; together with a statement that the content of the "Sequence Listing" information recorded in computer readable form is identical to the written (on paper or compact disc) "Sequence Listing" and, where applicable, includes no new matter, as required by 37 CFR §1.821(e), §1.821(f), §1.821(g), §1.825(b), or §1.825(d).

An executed Declaration and Power of Attorney for the above-identified application was filed on March 15, 2002; hence, the Applicants have completely replied to missing item (a) within the permitted extended timeframe.

Enclosed herewith are items (b) and (c).

More specifically, enclosed herewith are substitute drawings for each of Figures 1, 2, 3, 4 and 5, such that, each and every of these substitute drawings is in full compliance with 37 CFR §1.84, including 37 CFR §1.84(g)(margins). In addition,

- (1) substitute drawing "Figure 1" maintains its reference to SEQ ID NO:1;
- (2) substitute drawing "Figure 2" (now two pages to comply with the margins requirement under 37 CFR §1.84(g)), to enable the Patent In 3.1 software, now refers separately to each of the four sequences depicted as Seq. ID No. 3A dPTH1 (canine), Seq. ID No. 3B rPTH1 (rat), Seq. ID No. 3C mPTH1 (mouse), and Seq. ID No. 3D hPTH1 (human);
- (3) substitute drawing "Figure 3," to enable the Patent In 3.1 software, now refers separately to each of the four sequences depicted as Seq. ID No. 2A dPTH1 (canine), Seq. ID No. 2B rPTH1 (rat), Seq. ID No. 2C mPTH1 (mouse), and Seq. ID No. 2D hPTH1 (human);
- (4) substitute drawing "Figure 4" has been amended to read "Figure 4" versus "Fig. 4;" and
- (5) substitute drawing "Figure 5" has been amended to read "Figure 5" versus "Fig. 5."

Each of the substitute drawings has been labeled on the reverse side with a label providing: the number of the figure, PC10891AGPR, Pfizer Inc., and the name of the Attorney for the Applicants. None of the subject matter described or depicted in each or any of such substitute drawings represents new matter, as all of the subject matter, including all of the sequences of the "Sequence Listing" prepared using the PatentIn 3.1 software were completely described in the application as originally filed. The PatentIn 3.1 software has necessitated additional Seq. ID Nos. but only in reference to subject matter fully described in the application as originally filed. Hence, Applicants have completely replied to missing item (b) within the permitted extended timeframe, without the addition of any new matter.


Further enclosed, in response to missing item (c), is an initial computer readable form (CRF) copy of the "Sequence Listing," (one floppy disk, labeled PC10891AGPR, Application No. 09/943,446, PatentIn 3.1, Sequence Listing, Pfizer Inc.), an initial paper of the "Sequence Listing," (seventeen (17) pages) as well as an amendment directing its entry into the application (part of "statement"); together with a "statement" that the content of the "Sequence Listing" information recorded in computer readable form is identical to the written on paper ("Sequence Listing") (one (1) page) and, where applicable, includes no new matter, as required by 37 CFR §1.821(e), §1.821(f), §1.821(g), §1.825(b), or §1.825(d).

The Commissioner is hereby authorized to charge the amount of \$500 (\$1390 (fee for 4 months) minus \$890 (fee for 3 months previously paid pursuant to reply filed March 15, 2002) and any additional fees required to Deposit Account No. 16-1445, or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

A copy of the NOTICE TO FILE MISSING PARTS mailed October 15, 2001, as well as a copy of the NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL) mailed April 5, 2002 are enclosed.

Respectfully submitted,

Date: April 15, 2002



Jennifer A. Kispert
Reg. No. 40,049
Attorney for Applicants

Pfizer Inc.
Patent Department, MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 715-5747

2022-04-15 09:44:00